INTRODUCTION
The combination of chemotherapy with an anti-CD20 monoclonal antibody, referred to as chemoimmunotherapy, has been the mainstay of therapy for chronic lymphocytic leukemia (CLL). While a subset of patients achieve durable remissions, most relapse within a few years. 1,2 Clonal evolution leads to the expansion of genetically altered cells that dominate at the time of relapse, limiting efficacy of repeat chemotherapy. 3 In particular, patients with TP53 aberration, either due to deletion of chromosome 17p (del(17p)) or TP53 mutation, relapse early after frontline chemoimmunotherapy with a median progression-free survival (PFS) of less than 2 years. 4,5 Toxicity of chemoimmunotherapy can be limiting especially for the majority of patients with CLL who are older than 65. While reduced-intensity regimens are less toxic, durability of response is inferior. [6] [7] [8] Targeted therapy with kinase inhibitors is emerging as an alternative to conventional therapy for CLL. [9] [10] [11] [12] [13] Activation of B-cell receptor (BCR) signaling through selfassociation or interactions with autoantigens is a key driver of CLL pathogenesis. [14] [15] [16] [17] Ibrutinib covalently binds Bruton's tyrosine kinase (BTK) leading to sustained inhibition of BCR and NF-κB signaling and tumor proliferation. 18, 19 In randomized trials, ibrutinib induced higher overall response rates (ORR) and extended survival compared to the comparator treatment for both relapsed and/or refractory CLL (RR-CLL) and treatmentnaïve CLL (TN-CLL). 9, 10 In contrast to the experience with chemoimmunotherapy, response to ibrutinib appears to be independent of TP53 aberration. 11, 20, 21 However, in RR-CLL with del(17p), one study reported 2-year PFS of 63%. 11 In contrast, we previously reported 2-year PFS of 82% in 51 patients with TP53 aberration (del(17p) and/or TP53 mutation), the majority of whom received ibrutinib as first-line therapy. 21 At the time of progression, mutations in PLCG2 and BTK that reduce the inhibitory effects of ibrutinib are often present. [22] [23] [24] [25] [26] [27] Computational models that incorporate estimates of mutation frequency and growth kinetics, suggest that subclones carrying these mutations likely exist before initiation of ibrutinib therapy. 28 For personal use only. on March 10, 2018. by Carsten Niemann www.bloodjournal.org From 5 Ibrutinib has generally been found to have a favorable safety profile. However, one center reported an estimated cumulative incidence of non-relapse discontinuation of ibrutinib in 15.6% at 18 months. 29 Further, the rate of atrial fibrillation is higher in ibrutinib-treated patients compared to control arms in randomized trials. 30 Finally, the impact of chronic inhibition of BTK on infection risk remains to be better defined. While, the frequency of infections, in particular respiratory infections, has been reported to decrease on continuous therapy, 20 and increases in serum IgA on ibrutinib are associated with a lower risk of infections, 31 others report an apparent increase in some opportunistic infections during ibrutinib therapy, including Pneumocystis jirovecii pneumonia and invasive fungal infections. 32, 33 Additional information on safety and efficacy of long-term therapy with ibrutinib will help estimate risks and expected benefit for different patient groups. Here we report the results with single-agent ibrutinib in patients with TP53 aberration or age 65 years or older enrolled in an investigator-initiated phase II study. Our data suggest that for a large proportion of CLL patients, ibrutinib monotherapy provides durable disease control.
PATIENTS, MATERIALS, AND METHODS

Study design and participants
This phase 2, open-label, single-center, study was approved by the Institutional Review Board (clinicaltrials.gov; NCT01500733). All patients provided written informed consent.
Eligibility criteria included active CLL or small lymphocytic lymphoma requiring therapy, 34 and del(17p) by fluorescence in situ hybridization (FISH) The primary endpoint was response after 6 cycles of therapy. Secondary endpoints included safety, tolerability, overall survival (OS), PFS, and best response. Data cut-off for this report was December 31, 2017. Non-hematologic AEs were graded by using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Hematologic AEs and responses were called based on the International Workshop on CLL (iwCLL) 2008 criteria, incorporating recent updates (Table S1 ). 34, 35 At 2, 6, 12 months, and yearly thereafter, CT, bone marrow biopsies, and flow cytometry were performed. Spleen volume was calculated from CT using the Vitrea Core Workstation Server, version 6.6 (Vital Images, Minnetonka, MN, USA). Normal spleen volume was considered less than 315mL. We previously reported the activity and safety data of the TP53 cohort (51 patients with TP53 aberration) at a median follow-up of 24 months. 21
Flow cytometry
Flow cytometry to quantify residual disease used methods recommended by European Research Initiative in CLL. 36 Minimal residual disease (MRD) negativity was defined as < 1 CLL cell in 10,000 (<10 -4 ) leukocytes assessed.
Statistical analysis
We used a Simon's minimax two-stage design to test the null hypothesis that the ORR method and compared between subgroups by the log-rank test. Response rates were estimated by the proportions for all patients and subgroups, their 95% confidence intervals (CIs) were computed, and compared between subgroups by Fisher's exact test. Wilcoxon signed-rank test was used to assess the change in the quantification of MRD. Spearman's analysis was used to assess the correlation between blood and bone marrow MRD. Statistical analyses were conducted using R version 3.4.0 (R Foundation for Statistical Computing).
Role of the funding source
The trial was designed by the investigators, and a draft of the protocol was submitted to Pharmacyclics for comments. The study was funded by the Intramural Research Program of National Heart, Lung and Blood Institute, and National Cancer Institute at the National Institutes of Health (NIH). Pharmacyclics provided the study drug. All data were collected by the investigators and stored at NIH. The investigators analysed the data and wrote the manuscript. A draft of the manuscript was submitted to Pharmacyclics for comments. The corresponding author had full access to all the data in the study and had final responsibility for the content of the report and the decision to submit for publication.
RESULTS
Patient characteristics and disposition
Between December 2011 and January 2014, 86 patients were enrolled; 51 were eligible due to TP53 aberration (TP53 cohort) and 35 due to age ≥ 65 years (elderly cohort; Figure S1 ; progression; three from infections, and one due to sudden, presumably cardiac death.
Twenty (23.3%) patients discontinued ibrutinib due to progressive disease, and five (5.8%) due to AEs, including newly diagnosed lung and ovarian cancer in one patient each. Six (7.0%) patients withdrew consent for various reasons. Two patients that did not meet enrollment criteria were removed and are included in the safety analysis only.
Safety
Treatment-related AEs leading to treatment discontinuation were, in one patient each, asymptomatic interstitial pulmonary infiltrates, progressive multifocal leukoencephalopathy on concurrent mycophenolate mofetil, and persistent grade 3 diarrhea with biopsy-proven microscopic colitis. Two (2.3%) patients discontinued due to second malignancies requiring systemic therapy. Nine (10.5%) patients required a dose reduction, six for atrial fibrillation, one for grade 3 rash, one for grade 3 diarrhea, and one patient requested a reduction for grade 2 arthralgia. Treatment-emergent grade 3 or 4 hematologic AEs were neutropenia in 33 (38.4%), thrombocytopenia in 13 (15.1%), and anemia in 6 (7.0%) patients, primarily during the first few months on ibrutinib (Table S3 ). Most hematologic AEs were attributable to disease and improved with ibrutinib. Most non-hematologic AEs were grade 1 or 2 and consistent with prior experience and USPI. Grade 3 or 4 non-hematologic AEs reported in 2 or more patients were infection (9.3%), atrial fibrillation ( 
Response
Eighty-one patients were evaluable for response at 6 months, the protocol defined primary endpoint (Table 2) . Three patients were not evaluable; two had died in the first two months, and one patient developed lung cancer. ORR for all patients was 95.1% (95% CI, 87.8-98.6), 95.8% for the TP53 cohort (95% CI, 85.7-99.5), 93.9% for the elderly cohort (95% CI, 79.8-99.3) and was not significantly different between subgroups stratified by treatment history, age, bulky lymphadenopathy, splenomegaly, IGHV subgroups, and baseline β 2-microglobulin (all P>.05).
Disease burden progressively decreased in all anatomic compartments ( Figure S2 ) with time on ibrutinib. At 3 years, the median reduction was 97% in absolute lymphocyte count (ALC), 94% in bone marrow, 89% in sum of the product of target lymph nodes, and 89% in spleen volume. The cumulative complete response (CR) rate was 9.9% at 2 years, 21.0% at 3 years, and reached 28.4% at 5 years ( Figure 1A) . No clinical or laboratory parameter was significantly associated with different CR rates ( Figure 1B ).
Next, we scored each of the iwCLL response criteria in each patient to investigate which criteria were not consistent with CR ( Figure 1C ). In order of decreasing frequency, the three most common were persistent splenomegaly (volume >315mL) in 33 (40.7%) of 81 patients, residual lymph nodes (diameter ≥ 1.5cm) in 27 (33.3%), and persistent lymphocytosis (ALC ≥ 4,000/µL) in 23 (28.4%). In 36 (44.4%) patients, more than one requirement for CR was not met.
Minimal residual disease
CLL burden, quantified by flow cytometry at 6 and 12 months and annual time-points thereafter, significantly decreased in both blood and bone marrow ( Figure 2AB ). Past the first year, the disease burden decreased by 33% in blood and 25% in marrow with each additional year of treatment ( Figure S3 ). The median MRD at 3 years was 5.3x10 -2 CLL cells/leukocyte in blood and 7.3x10 -2 in bone marrow. The median MRD at 4 years was 4.3x10 -2 CLL cells/leukocyte in blood and 6.2x10 -2 in bone marrow. Measurements 1 1 in the two compartments were highly correlated (Spearman's ρ =.70 at 3 years, .89 at 4 years; both P<.0001; Figure 2C -F).
Residual disease burden was similar in patients stratified by cohort or prior treatment status. However, patients with mutated IGHV had significantly more residual disease in the blood than patients with unmutated IGHV (Figure 2A ). MRD levels in bone marrow
were not significantly different between two IGHV subgroups ( Figure 2B ). MRD negativity (<10 -4 ) was achieved in 1 of 64 patients in peripheral blood, and in 2 of 51 in bone marrow aspirate at 3 years, and 5 of 48 patients in peripheral blood, and 2 of 25 patients in bone marrow aspirate at 4 years. Seven patients in CR achieved MRD negativity in either blood or bone marrow. One patient with MRD negativity in blood at 3 and 4 years was not in CR due to persistent splenomegaly (residual spleen volume:
442mL at 4 years).
We divided patients into two subgroups based on 3-year peripheral blood MRD levels using the cutoff of 10 -2 as previously described by others: MRD-low (<10 -2 ), and MRDhigh (≥10 -2 ). 37 Among 64 patients on ibrutinib at 3 years, 16 (25%) patients were MRDlow, 47 (75%) were MRD-high, and one patient missed MRD assessment. The CR rate was 37.5% in the MRD-low group and 21.3% in the MRD-high group (P=.3; Figure S4 ).
Nine (19.1%) of 47 patients in the MRD-high group, and one (6.3%) of 16 patients in the MRD-low group subsequently progressed. PFS was not statistically different between the two groups (P=.5).
Disease progression and survival
With the median follow-up of 57 months, the estimated 5-year PFS was 58.2% for the TP53 cohort (95% CI, 44.5-74.5) and 81.2% for the elderly cohort (95% CI, 67.1-98.3) (P=.026); and the median OS was 75.7% (95% CI, 64.7-88.7) and 83.8% (95% CI, 70-100), respectively (P=.10). In both cohorts, PFS was more favorable for patients receiving ibrutinib as a first-line therapy (Figure 3 ). In the TP53 cohort, the estimated 5- 98.1) versus 53.7% (95% CI, 33.4-86.4), respectively (P=.023). In the elderly cohort, no progression or death occurred in TN-CLL, and in RR-CLL, the estimated 5-year PFS was 64.8% (95% CI, 43.9-95.7) and OS was 71.6% (95% CI, 51.2-100). There was no statistically significant difference in PFS and OS between subgroups divided by IGHV mutation status (all P>.1, Figure S5 ).
Overall, 20 (23.8%) patients progressed. The median time-to-progression was 37.6 months (range, 0.4-54.7). Four (4.8%) patients had Richter's transformation and two (2.4%) had prolymphocytic transformation. 21, 25 All transformation events occurred within the first 15 months on study. Two patients with Richter's transformation never achieved a response; all others initially responded, three having achieved CR before progressing ( Figure S6 ). Fourteen patients progressed with CLL; 12 (85.7%) of these had BTK and/or PLCG2 mutations at progression. 25 Of nine patients maintained on dose-reduced ibrutinib, only one has progressed to date. Thirteen patients with progressive CLL received salvage therapy with venetoclax or idelalisib plus rituximab. One patient died before initiation of subsequent therapy. The estimated median survival for patients with progressive CLL was 20.5 months from the time of progression with 7 (35.0%) of 20 patients alive at data cutoff.
DISCUSSION
In most cancers, with the notable exception of chronic myeloid leukemia, single-agent therapy is limited by the rapid emergence of drug resistance. Our data with extended follow-up of patients on ibrutinib suggests that a large proportion of CLL patients achieve durable disease control on single-agent ibrutinib with excellent tolerability. The study population is representative of the clinical spectrum of CLL comprising both previously untreated patients as well as patients relapsing after up to 7 prior regimens, with a majority of patients older than 65. However, due to the preferential inclusion of patients with TP53 aberration, the genetic risk profile is skewed towards high-risk disease.
3
We previously reported 2-year PFS of 82% for the TP53 cohort. 21 With the median follow-up of 57 months, the estimated 5-year PFS for these patients decreased to 58.2% (95% CI, 44.5-74.5). The majority of patients progressing had both TP53 aberration and RR-CLL. Notably, the estimated 5-year PFS in the current study was 74.4% (95% CI, 60.2-92.1) for TN-CLL patients with TP53 aberration compared to 19.4% (95% CI, 6.3-60) for those with RR-CLL (P=.0002). These results compare favorably to those achieved with chemoimmunotherapy. In the CLL8 trial, 68% of TN-CLL patients with del(17p) achieved a response to fludarabine, cyclophosphamide, and rituximab with the median PFS of 11.3 months. 4 In the MD Anderson series, 23% of patients with del(17p) were refractory to first-line therapy, the median PFS was 14 months, and 23% developed Richter's transformation. 38 In the current study report, none of the previously untreated patients without TP53 aberration progressed on ibrutinib. Also, patients with RR-CLL without TP53 aberration did well, consistent with data from company-sponsored trials with 3-years of follow-up. 39 Thus, TP53 aberration and prior treatment history are important determinants of PFS on ibrutinib. These observations raise the question whether use of chemoimmunotherapy in first-line could compromise success of subsequent therapy with ibrutinib, or conceivably other targeted agents. 40 Onset of response was quick, providing symptomatic relief within days, but long-term therapy was required for CRs. The most common reason for not achieving CR was residual lymphadenopathy or splenomegaly on CT scans. We routinely included bone marrow biopsies, which allowed continuous assessment of disease status in this compartment. Only in three patients were bone marrow findings responsible for not meeting CR criteria. MRD negative remissions, defined as less than 10 -4 CLL cells per leukocyte, remained uncommon. MRD-low remissions (<10 -2 ) in the blood were observed in 25% of patients at 3 years. MRD measurements in blood and bone marrow were highly correlated. Thus, bone marrow examination seems to add little to response assessments in patients on ibrutinib.
4
The safety profile of continuous therapy with ibrutinib for over 5 years was similar to what has been reported with shorter treatment duration. 9, 10, 21 No new safety signals emerged and most AEs were grade 1 or 2, and transient. The most common treatmentrelated grade 3 or higher AEs were infection (9.3%) and atrial fibrillation (5.8%). With our extended follow-up, the cumulative incidence of any grade atrial fibrillation at 19.8% is the highest reported. 30 However, the rate of 6.4 per 100 patient-years in our study is consistent with the incidence of 6 per 100 patient-years reported from the pooled analysis of 4 clinical trials using ibrutinib in CLL and MCL. 30 One patient with atrial fibrillation chose to discontinue ibrutinib due to recurrent grade 2 events, all other patients remained on study in consultation with cardiologists. Overall, five (5.8%) patients had to discontinue therapy due to treatment-emergent AEs. The low rate of study discontinuation is notable and, in addition to the good tolerability of the drug, might reflect the high proportion of patients with TP53 aberration who were determined to continue ibrutinib for as long as possible.
In summary, long-term administration of ibrutinib was well tolerated with deepening of 
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